# Aureka Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aureka-biotechnologies

- Industry: Biotechnology
- Headquarters: Laguna Hills, US
- Website: www.aurekabio.com
- Total disclosed funding: $235M
- Latest round: Series B (Oct 19, 2026)
- Investors on record: 9

## About

Based in Laguna Hills, US, and established in 2023, Aureka Biotechnologies, Inc.trading under the name Aureka, was founded to provide drug discovery services for complex targets in the pharmaceutical industry. The company was co-founded by Dr. Weian Zhao (CEO), Alon Wellner and Shuangjia Zheng with a core team focused on integrating microfluidic systems, synthetic biology, and artificial intelligence. Since its inception, the firm has advanced from platform development to large-scale molecular design and has established partnerships with several multinational pharmaceutical companies. In August 2026, Aureka raised USD 100 million in series B funding from Granite Asia, HighLight Capital, MPCi, and NRL Capital.

The company works with multinational pharmaceutical and biotechnology firms to provide its proprietary AuraIDE™ intelligent antibody design platform. Its technology solutions leverage high-throughput microfluidic systems to characterize complex drug functions, such as agonistic activity, endocytosis, and brain permeability, delivering commercial-ready pipeline data packages (including pre-CMC and pre-toxicology data) within 9 to 12 months. The company’s internal pipeline focuses on antibody drug development for cardiovascular, metabolic, immunological, and central nervous system diseases.

The company generates revenue from B2B business development transactions and project collaborations with pharmaceutical and biotechnology companies. This includes fees for the delivery of differentiated functional molecules designed by AI agents and the provision of comprehensive drug pipeline data packages.

The company will use the August 2026 funding to train biological AI models and improve its drug discovery platform.

## Funding rounds

- Series B, Oct 19, 2026, $100M — Granite Asia, HighLight Capital, MPCi, NRL Capital
- Series B, Aug 10, 2026, $100M — Granite Asia, Qiming Venture Partners, HighLight Capital, MPCi, NRL Capital
- Series A, Apr 28, 2026, $35M — Qiming Venture Partners, 5Y Capital, MPCi, HSG, BioTrack Capital, NRL Capital
- Series A, Nov 10, 2025 — Qiming Venture Partners, 5Y Capital, NRL Capital
- Seed, Jun 25, 2023 — K2VC, NRL Capital

## Investors

- K2VC (https://capitalatlas.ai/funds/k2vc) — Seed
- NRL Capital (https://capitalatlas.ai/funds/nrl-capital) — Seed, Series A, Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series A, Series B
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A
- MPCi (https://capitalatlas.ai/funds/mpci) — Series A, Series B
- HSG (https://capitalatlas.ai/funds/hsg) — Series A
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A
- Granite Asia (https://capitalatlas.ai/funds/granite-asia) — Series B
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B